Draft Adhesion Barrier Guidance Overly Burdensome - Industry Task Force
This article was originally published in The Gray Sheet
Executive Summary
FDA's proposal that clinical studies of resorbable adhesion barrier devices have endpoints other than adhesion reduction is overly burdensome to manufacturers, according to an industry task force.
You may also be interested in...
Adhesion Barrier Final Guidance Removes Surrogate Endpoint Distinction
FDA's final guidance for resorbable adhesion barrier devices used in abdominal and/or pelvic surgery eliminates the definition of adhesion reduction as a surrogate endpoint
Adhesion Barrier Final Guidance Removes Surrogate Endpoint Distinction
FDA's final guidance for resorbable adhesion barrier devices used in abdominal and/or pelvic surgery eliminates the definition of adhesion reduction as a surrogate endpoint
Biomatrix Resolves FDA Concerns Over Anti-adhesion Claims For HylaSine
Biomatrix removed a March 29 press release announcing approval of the HylaSine sinus gel stent from its website after receiving an FDA warning letter May 24 citing the firm for promotional violations.